$42.91
+0.02 (+0.05%)
Open$42.94
Previous Close$42.89
Day High$42.95
Day Low$42.89
52W High$127.90
52W Low$38.06
Volume—
Avg Volume70.7K
Market Cap124.47M
P/E Ratio—
EPS$-38.31
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+4.4% upside
Current
$42.91
$42.91
Target
$44.79
$44.79
$31.89
$44.79 avg
$48.55
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 10.25M | 53.02M | 47.19M |
| Net Income | -110,695,812 | 1.91M | 1.39M |
| Profit Margin | -1,079.9% | 3.6% | 2.9% |
| EBITDA | -109,958,977 | 2.67M | 2.51M |
| Free Cash Flow | — | 1.24M | 802.3K |
| Rev Growth | — | +15.8% | -2.9% |
| Debt/Equity | 0.06 | 0.46 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |